Evaluation of two 125I-radiolabeled acridine derivatives for Auger-electron radionuclide therapy of melanoma

Investigational New Drugs

Volumn 32, Issue 4, 2014, Pages 587-597

  Gardette, Maryline ^a,b,c   Viallard, Claire ^a,b,c   Paillas, Salomé ^d,e   Guerquin Kern, Jean Luc ^f,g   Papon, Janine ^a,b,c   Moins, Nicole ^a,b,c   Labarre, Pierre ^a,b,c   Desbois, Nicolas ^h   Wong Wah Chung, Pascal ⁱ   Palle, Sabine ^j   Wu, Ting Di ^f,g   Pouget, Jean Pierre ^d,e   Miot Noirault, Elisabeth ^a,b,c   Chezal, Jean Michel ^a,b,c   Degoul, Francoise ^a,b,c  

^a UNIVERSITÉ CLERMONT AUVERGNE   (France)

^b INSERM   (France)

^c CENTRE JEAN PERRIN   (France)

^d INSTITUT DE RECHERCHE EN CANCÉROLOGIE DE MONTPELLIER   (France)

^e UNIV MONTPELLIER   (France)

^f INSTITUT CURIE   (France)

^g Centre Universitaire   (France)

^h UNIVERSITÉ DE BOURGOGNE   (France)

ⁱ AIX MARSEILLE UNIVERSITY   (France)

^j UNIVERSITÉ JEAN MONNET   (France)

more..

Author keywords

Acidic vesicles; Auger electron emitter; Iodine 125; Melanin; Melanoma; Targeted radionuclide therapy

Indexed keywords

ACRIDINE DERIVATIVE; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT;

ANIMAL; C57BL MOUSE; DIET THERAPY; ELECTRON; HUMAN; MALE; MELANOMA, EXPERIMENTAL; METABOLISM; MOUSE; TUMOR CELL LINE;

ACRIDINES; ANIMALS; CELL LINE, TUMOR; ELECTRONS; HUMANS; IODINE RADIOISOTOPES; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; RADIOPHARMACEUTICALS;

EID: 84904535695     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-014-0086-5     Document Type: Article

References (30)

1. Little EG, Eide MJ (2012) Update on the current state of melanoma incidence. Dermatol Clin 30:355-361
2. Finn L, Markovic SN, Joseph RW (2012) Therapy for metastatic melanoma: the past, present, and future. BMC Med 10:23
3. Smalley KS, Aplin AE, Flaherty KT, Hoeller C, Bosserhoff AK, Haass NK, Bosenberg M, Ribas A, Barnhill R, Kudchadkar R, Messina JL (2012) Meeting report from the 2011 International Melanoma Congress, Tampa, Florida. Pigment Cell Melanoma Res 25:E1-E11
4. Davies AJ (2007) Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I(131) tositumomab. Oncogene 26:3614-3628
5. Miao Y, Quinn TP (2008) Peptide-targeted radionuclide therapy for melanoma. Crit Rev Oncol Hematol 67:213-228
6. Eberle AN, Bapst JP, Calame M, Tanner H, Froidevaux S (2010) MSH radiopeptides for targeting melanoma metastases. Adv Exp Med Biol 681:133-142
7. Koch SE, Lange JR (2000) Amelanotic melanoma: the great masquerader. J Am Acad Dermatol 42:731-734 (Pubitemid 30252874)
8. Nikkola J, Vihinen P, Vlaykova T, Hahka-Kemppinen M, Kahari VM, Pyrhonen S (2002) High expression levels of collagenase-1 and stromelysin-1 correlate with shorter disease-free survival in human metastatic melanoma. Int J Cancer 97:432-438 (Pubitemid 34027800)
9. Ghanem N, Altehoefer C, Hogerle S, Nitzsche E, Lohrmann C, Schafer O, Kotter E, Langer M (2005) Detectability of liver metastases in malignant melanoma: prospective comparison of magnetic resonance imaging and positron emission tomography. Eur J Radiol 54:264-270 (Pubitemid 40523619)
10. Quinn T, Zhang X, Miao Y (2010) Targeted melanoma imaging and therapy with radiolabeled alpha-melanocyte stimulating hormone peptide analogues. In: G Ital Dermatol Venereol vol 145. Italy, pp 245-258
11. Link EM (1999) Targeting melanoma with 211At/131I-methylene blue: preclinical and clinical experience. Hybridoma 18:77-82
12. Bonnet-Duquennoy M, Papon J, Mishellany F, Labarre P, Guerquin-Kern JL, Wu TD, Gardette M, Maublant J, Penault-Llorca F, Miot-Noirault E, Cayre A, Madelmont JC, Chezal JM, Moins N (2009) Targeted radionuclide therapy of melanoma: anti-tumoural efficacy studies of a new 131I-labelled potential agent. Int J Cancer 125:708-716
13. Bonnet M, Mishellany F, Papon J, Cayre A, Penault-Llorca F, Madelmont JC, Miot-Noirault E, Chezal JM, Moins N (2010) Anti-melanoma efficacy of internal radionuclide therapy in relation to melanin target distribution. Pigment Cell Melanoma Res 23:e1-e11
14. Joyal JL, Barrett JA, Marquis JC, Chen J, Hillier SM, Maresca KP, Boyd M, Gage K, Nimmagadda S, Kronauge JF, Friebe M, Dinkelborg L, Stubbs JB, Stabin MG, Mairs R, Pomper MG, Babich JW (2010) Preclinical evaluation of an 131I-labeled benzamide for targeted radiotherapy of metastatic melanoma. Cancer Res 70:4045-4053
15. Oriuchi N, Higuchi T, Hanaoka H, Iida Y, Endo K (2005) Current status of cancer therapy with radiolabeled monoclonal antibody. Ann Nucl Med 19:355-365 (Pubitemid 41265327)
16. Chirumamilla A, Travin MI (2011) Cardiac applications of 123I-mIBG imaging. Semin Nucl Med 41:374-387
17. Al-Haj AN, Lobriguito AM, Lagarde CS (2004) Radiation dose profile in 125I brachytherapy: an 8-year review. Radiat Prot Dosim 111:115-119 (Pubitemid 39359270)
18. Kassis AI, Adelstein SJ (2005) Radiobiologic principles in radionuclide therapy. J Nucl Med 46(Suppl 1):4S-12S (Pubitemid 47619013)
19. Barendswaard EC, Humm JL, O'Donoghue JA, Sgouros G, Finn RD, Scott AM, Larson SM, Welt S (2001) Relative therapeutic efficacy of (125)I- and (131)I-labeled monoclonal antibody A33 in a human colon cancer xenograft. J Nucl Med 42:1251-1256 (Pubitemid 32717846)
20. Ickenstein LM, Edwards K, Sjoberg S, Carlsson J, Gedda L (2006) A novel 125I-labeled daunorubicin derivative for radionuclide-based cancer therapy. Nucl Med Biol 33:773-783 (Pubitemid 44247737)
21. Desbois N, Gardette M, Papon J, Labarre P, Maisonial A, Auzeloux P, Lartigue C, Bouchon B, Debiton E, Blache Y, Chavignon O, Teulade JC, Maublant J, Madelmont JC, Moins N, Chezal JM (2008) Design, synthesis and preliminary biological evaluation of acridine compounds as potential agents for a combined targeted chemo-radionuclide therapy approach to melanoma. Bioorg Med Chem 16:7671-7690
22. Gardette M, Papon J, Bonnet M, Desbois N, Labarre P, Wu TD, Miot-Noirault E, Madelmont JC, Guerquin-Kern JL, Chezal JM, Moins N (2010) Evaluation of new iodinated acridine derivatives for targeted radionuclide therapy of melanoma using 125I, an Auger electron emitter. Investig New Drugs 29:1253-1263
23. Svensson SP, Lindgren S, Powell W, Green H (2003) Melanin inhibits cytotoxic effects of doxorubicin and daunorubicin in MOLT 4 cells. Pigment Cell Res 16:351-354 (Pubitemid 36950567)
24. Larsen AK, Escargueil AE, Skladanowski A (2000) Resistance mechanisms associated with altered intracellular distribution of anticancer agents. Pharmacol Ther 85:217-229 (Pubitemid 30160791)
25. Duvvuri M, Gong Y, Chatterji D, Krise JP (2004) Weak base permeability characteristics influence the intracellular sequestration site in the multidrug-resistant human leukemic cell line HL-60. J Biol Chem 279:32367-32372, United States (Pubitemid 39014690)
26. Guerquin-Kern JL, Wu TD, Quintana C, Croisy A (2005) Progress in analytical imaging of the cell by dynamic secondary ion mass spectrometry (SIMS microscopy). Biochim Biophys Acta 1724:228-238 (Pubitemid 41080032)
27. Chen KG, Leapman RD, Zhang G, Lai B, Valencia JC, Cardarelli CO, Vieira WD, Hearing VJ, Gottesman MM (2009) Influence of melanosome dynamics on melanoma drug sensitivity. J Natl Cancer Inst 101:1259-1271
28. Wolf M, Eskerski H, Bauder-Wust U, Haberkorn U, Eisenhut M (2006) Alkylating benzamides with melanoma cytotoxicity: experimental chemotherapy in a mouse melanoma model. Melanoma Res 16:487-496 (Pubitemid 44934706)
29. Santoro L, Boutaleb S, Garambois V, Bascoul-Mollevi C, Boudousq V, Kotzki PO, Pelegrin M, Navarro-Teulon I, Pelegrin A, Pouget JP (2009) Noninternalizing monoclonal antibodies are suitable candidates for 125I radioimmunotherapy of small-volume peritoneal carcinomatosis. J Nucl Med 50:2033-2041
30. Wolf M, Bauder-Wust U, Eskerski H, Bauer C, Eisenhut M (2007) Role of acidic cell organelles in the higher nonmelanoma retention of melanoma markers based on N-(2-dialkylaminoethyl)benzamides and the cytotoxicity of alkylating benzamides. Melanoma Res 17:61-73 (Pubitemid 46673899)